HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning Letters Increasingly Targeting Internet Claims

This article was originally published in The Tan Sheet

Executive Summary

More than 80% of the warning letters concerning OTC drug and dietary supplement products sent in the last few months have focused on Internet claims

You may also be interested in...



Noni warning letter

Claims that Noni Juice Liquid Herbal Supplement and Noni Extra Strength Cleansing Formula AM/PM treat diabetes, asthma, cataracts, high blood pressure, breast cancer, depression and migraine render the products unapproved new drugs, FDA tells Carolina, Puerto Rico-based Mundo Natural in an April 29 warning letter. Similar claims about relief of arthritis, headaches and the immune system made for other noni juice products earned warning letters for three different companies in 2002 (1"The Tan Sheet" July 15, 2002, p. 9)...

Nature’s Youth Supplement Relabeled Without Growth Factor Reference

Marketing of Nature's Youth dietary supplement has resumed in packaging that no longer refers to human growth factor or anti-aging claims, the product's Centerville, Mass.-based marketer said. The supplement's name also has been revised from Nature's Youth hGH

Niacin Supplement For High Cholesterol Targeted In Warning Letter

Upsher-Smith Labs' Slo-Niacin was cited by FDA in a recent warning letter for claims it has made to treat hypercholesterolemia

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel